Keyword: Biocon


Viatris Selling Biosimilars Unit to Biocon for $3 Billion

17.03.2022 -

Viatris, the new US pharma created in the 2020 merger of Mylan and Pfizer’s Upjohn off-patent franchise, is selling its biosimilars portfolio to Biocon Biologics for up...

Chemistry & Life Sciences

Innovation and Creativity in the Pharmaceutical Industry

30.04.2021 -

The International Society for Pharmaceutical Engineering (ISPE) announced the 2021 Facility of the Year Awards (FOYA) Category Winners—including two winners of Special...


Sandoz and Biocon Collaborate on Biosimilars

24.01.2018 - Sandoz, the generics subsidiary of Novartis, is collaborating with Biocon, an India-based biopharmaceuticals producer, to develop, manufacture and commercialize multiple...


Sanofi Charges Mylan With Lantus Breach

07.11.2017 - Sanofi is pursuing another US competitor for alleged breach of the patent for its top-selling diabetes drug insulin glargine (branded as Lantus and Lantus SoloStar), which together...


Indian Companies to Policymakers: Shape up, or we’ll ship out

09.09.2013 - After the rapid slide in India's rupee this year, the message from the country's corporate titans to the government is clear: shape up and fix the problems or more companies will...

Plant Construction & Process Technology

The World Of Biosimilars

30.05.2011 - Doubled-Edged Sword - The emergence of biosimilars has caused very large ripples in the biopharma pond, and has recently been called the most "disruptive technology" of the decade...